Schond Greenway

Schond Greenway

Plus aucun poste en cours
54 ans
Health Technology
Consumer Services
Finance

Profil

Schond L.
Greenway
worked at Halozyme Therapeutics, Inc. as Executive Director-Strategy & IR from 2013 to 2016.
Worked at Mesoblast Ltd. as VP & Global Head-Investor Relations from 2016 to 2021.
Worked at Avalo Therapeutics, Inc. as Chief Financial Officer & Treasurer from 2021 to 2022.
Worked at Definium Therapeutics, Inc. as Chief Financial Officer from 2022 to 2024.
Also held positions at DURECT Corp.
as VP-Investor Relations & Strategic Planning and at Barclays Capital, Inc. as Vice President-Healthcare.
Education includes undergraduate studies at Florida A&M University and an MBA from the University of Virginia Darden School of Business.

Anciens postes connus de Schond Greenway

SociétésPosteFin
DEFINIUM THERAPEUTICS, INC. Directeur Financier/CFO 03/05/2024
AVALO THERAPEUTICS, INC. Directeur Financier/CFO 14/02/2022
MESOBLAST LIMITED Investor Relations Contact 01/02/2021
HALOZYME THERAPEUTICS, INC. Investor Relations Contact 01/01/2016
DURECT Public Communications Contact -
Voir l'expérience en détail de Schond Greenway

Formation de Schond Greenway

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

54

Relations au 1er degré

8

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées8

Health Technology

Health Technology

Finance

Consumer Services

Health Technology

Health Technology

Consumer Services

Health Technology

  1. Bourse
  2. Insiders
  3. Schond Greenway
🔇